Recombinant Mouse BTLA Protein，His

BTLA (B and T Lymphocyte Attenuator) is a key immune checkpoint molecule that plays a critical role in modulating the immune response. It belongs to the CD28 family of co-receptors and is mainly expressed on B cells, T cells, and dendritic cells, where it functions as an inhibitory receptor, counteracting signals from costimulatory proteins such as CD28. Research into BTLA has gained significant attention due to its potential implications in cancer immunotherapy, autoimmune diseases, and infectious diseases. In tumor microenvironments, BTLA can inhibit T cell activation and proliferation, leading to immune evasion by cancer cells. This has prompted scientists to investigate the therapeutic potential of targeting BTLA to enhance anti-tumor immunity. Additionally, understanding the mechanisms by which BTLA regulates immune responses could provide insights into developing strategies for treating autoimmune conditions, where the immune system mistakenly attacks healthy tissues. Advances in recombinant protein technology enable the production of functional BTLA proteins for studies that elucidate its structure-function relationship, binding affinities, and downstream signaling pathways. Such studies are essential for developing novel immunotherapeutic approaches that can modulate BTLA signaling, thereby enhancing immune responses against tumors or offering regulatory control in autoimmune disorders. Overall, BTLA represents a promising target for enhancing the efficacy of immunotherapies, necessitating ongoing research to fully elucidate its role in immune regulation.